OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Oberstein on Data for Pamrevlumab Plus Nab-Paclitaxel/Gemcitabine in PDAC

January 28th 2025

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Dr Dizman on the Rationale of Evaluating CBM588 in Metastatic RCC

January 27th 2025

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC

January 27th 2025

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

January 27th 2025

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer

January 27th 2025

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

January 27th 2025

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC

January 25th 2025

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC

January 25th 2025

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Dr Hinchcliff on the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 25th 2025

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Dr Alencar on the Rationale of Investigating BTK Degraders in CLL

January 24th 2025

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer

January 24th 2025

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

Dr Al Hallak on the Associated Risks of Cirrhosis and Portal Hypertension in HCC

January 24th 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Dr Jurczak on the Role of Nemtabrutinib in R/R Follicular Lymphoma Management

January 23rd 2025

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.

Dr Singer on Choosing Between Frontline IO/IO and IO/TKI Regimens in RCC

January 23rd 2025

Adam E. Singer, MD, PhD, discusses factors that inform the choice between IO/IO and IO/TKI regimens for patients with renal cell carcinoma.

Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL

January 23rd 2025

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

Dr McGregor on Future Biomarker Analyses With Nivolumab Plus Ipilimumab in Bladder Cancer

January 23rd 2025

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Dr Zackon on Next Steps for Evaluating the Real-World Use of Bispecific Antibodies in R/R Myeloma

January 23rd 2025

Ira Zackon, MD, discusses the real-world use of bispecific antibodies for patients with R/R multiple myeloma in the community oncology setting.

Dr Berchuck on Next Steps for Evaluating a Novel Liquid Biopsy for PSMA in mCRPC

January 23rd 2025

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

Dr Braun on Future Directions for Research Into Protein Glycosylation in RCC

January 22nd 2025

David A. Braun, MD, PhD, discusses future directions for research into protein glycosylation as a biomarker of response in renal cell carcinoma.